Zymeworks Inc.

Zymeworks Bc Inc.

Agensys, Inc.

Stuart Daniel Barnscher

James R Rich

Geoffrey C Winters

Alexander Laurence Mandel

Tom Han Hsiao Hsieh

Graham Albert Edwin Garnett

Elyse Marie Josée Bourque

Rupert H Davies

Gerald J Rowse

Kevin Hamblett

Vincent K C Fung

John Stephen Babcook

Dunja Urosev

Jan Peter Bergqvist

Michael G Brant

Brian Alan Mendelsohn

Brandon Clavette

Danny Chui

Sukhbir Singh Kang

Peter Wing Yiu Chan

Duncan Browman

Robert William Gene

Manuel Michel Auguste Lasalle

Mark Edmund Petersen

Samir Das

Raffaele Colombo

Elyse Marie Josee Bourque

Andrea Hernandez Rojas

Julien Dugal-Tessier

Samuel Oliver Lawn

Ada G H Young

Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.

Antibody-drug conjugates targeting folate receptor alpha and methods of use

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose.

Anti-HER2 biparatopic antibody-drug conjugates and methods of use

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Cytotoxic and anti-mitotic compounds, and methods of using the same

Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.

Derivatives of dolaproine-dolaisoleucine peptides

The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the C-terminal amino acid extension are also provided. The present disclosure further provides nucleic acids encoding an antibody light chain polypeptide that includes a C-terminal amino acid extension including a cysteine residue. Pharmaceutical compositions including the antibodies or conjugates of the present disclosure are also provided, as are methods of making and use of the modified anti-bodies and conjugates of the present disclosure.

Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (&#x3c;3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR&#x2265;3.9 when administered at the same toxin dose.

Growing community of inventors

Vancouver, Canada

Stuart Daniel Barnscher